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Chordomas are rare neoplasm arising along the axial skeleton. Up to now, the most 
suitable therapeutic approach is based on a combination of surgical excision and 
radiotherapy. Chemotherapy in not applied due to its reported low efficacy. Recently, 
evidence on efficacy of Imatinib mesylate in two patients has been reported. We 
analyzed 14 chordoma samples for the expression of Imatinib mesylate targets by 
means of RT-PCR and immunohistochemistry and found that PDGFRα and 
PDGFRβ are in some cases expressed in neoplastic cells, while the stromal 
counterpart of the same tumor shows the above receptors. Findings on 
PDGFA/PDGFB expression suggest a receptor activated status. Our work provides 
new insights on the specific localization of Imatinib mesylate targets in skull base 
chordomas that could be taken in account for the setting up of a pharmacological 





Chordomas are uncommon slowly growing neoplasms of the axial skeleton with two 
main sites of origin, the sacrococcigeal region and the skull base (clivus). Treatment 
of chordomas is still controversial. Surgical excision followed by radiotherapy, in 
particular proton beam irradiation, seems to be related with the best tumor 
progression-free survival (1). Chemotherapy is not currently applied in clinical 
practice because of the described low efficacy(2-5). The course of the disease is 
often unfavorable because of local recurrence and eventually death. Recently Casali 
and his colleagues reported the compassionate use of Imatinib mesylate on 6 
patients affected by chordoma (1 skull base and 5 sacral chordomas), 4 of whom 
expressing PDGFRβ (6). Authors observed tumor colliquation in one patient and a 
decrease in tumor density in another one. The study revealed an antitumor activity of 
Imatinib mesylate. As this drug exerts its activity by inactivating PDGFRβ, PDGFRα 
and c-kit, it appears important to investigate their expression in a higher number of 
chordomas. We therefore evaluated the expression of PDGFRA, PDGFRB and KIT 
transcripts and proteins and the mRNA expression of their ligands PDGFA, PDGFB 
and SCF in 14 skull base chordoma (SBC) samples. 
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Materials and Methods 
Tumor samples 
The study was performed on 13 skull base chordoma samples and on a recurrence 
from one of them. Each patient underwent surgery at the Department of 
Neurosurgery of the San Raffaele Scientific Institute in Milan during the period from 
August 1997 to December 2005.  
Nine patients were male and four were female; the age ranged from 25 to 67 years 
(average 40,5 years). All the patients had been treated with radiotherapy. 
All patients gave informed consent to the study. 
 
RT-PCR analysis 
The expression analysis of Imatinib targets was performed by RT-PCR. RNA, 
isolated from 14 fresh or frozen chordoma samples, was carried out by means of 
Trizol reagent (Invitrogen, Carlsbad, California); 1μg of total RNA was reverse 
transcribed using ThermoScript RT-PCR System and oligo-dT primers for first-strand 
cDNA synthesis according to the instructions of the manufacturer (Invitrogen, 
Carlsbad, California). Specific primers for KIT, PDGFRA and PDGFRB were 
designed on different exons for each amplimer (Table I); the ligand primers were 




Immunohistochemical analysis was performed on formalin fixed paraffin embedded 
material. In 12 cases adequate histologic material was available. The following 
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antibodies were utilized: a rabbit polyclonal PDGF Receptor alpha Antibody 
(cod.3164, Cell Signaling Technology, Danvers, Massachusetts) diluted 1/100; a 
rabbit monoclonal PDGF Receptor beta Antibody (cod.3169, Cell Signaling 
Technology, Danvers, Massachusetts) diluted 1/50; a rabbit polyclonal antibody 
against c-kit (cod.A4502, Dako, Glostrup, Denmark), diluted 1/500. Briefly the 
histologic sections were deparaffinized, rehydrated and endogenous peroxidase 
activity was quenced with 3% Hydrogen peroxide; Tris buffer 0.05M with EDTA 
0.01M at pH9  was utilized as antigen retrieval for PDGFRα and PDGFRβ, whereas 
citrate buffer 0.01M pH 6 was employed for c-kit. The polymer system with DAB as 





We performed an expression study of PDGFRA, PDGFRB and KIT genes by 
RT-PCR and immunohistochemical analysis on 13 primary SBCs and on 1 
recurrence from one of them (Figure 1). 
The immunohistochemical analysis revealed that the tumor stroma cells were 
positive for PDGFRα and PDGFRβ expression in all analyzed samples (Figure 2). 
In most cases, the neoplastic cells showed focal expression of PDGFRα and 
PDGFRβ (Figure 2) mainly at the interface with the stromal component, while they 
were found to be diffusely expressed in 4 and in 3 chordomas respectively. PDGFRα 
and PDGFRβ were not observed to be expressed in neoplastic cells of 2 and 1 
chordomas respectively. c-Kit immunoreactivity was not detected in all but one 
samples; scattered mast cells served as an internal control in each case. 
For the samples where immunohistochemical analysis was not feasible, we report 
data from the RT-PCR analysis (Figure 1), which shows the transcripts of the three 
receptors in all samples but one, which lacks PDGFRB expression. 
We also investigated by RT-PCR analysis the expression of the above TK receptor 
ligands (PDGFA, PDGFB and SCF), which might prelude the receptor activation by 
means of an autocrine loop. In particular, SCF was found to be expressed only in 1 
tumor, while 8 chordomas showed both PDGFA and PDGFB mRNAs and 1 tumor 




In the present study we investigate the expression of Imatinib target receptors 
PDGFRA, PDGFRB and KIT transcripts and proteins, and of their ligand PDGFA, 
PDGFB and SCF mRNAs in 14 SBCs. The obtained evidence, indicating that all 
analyzed samples express at least one of the three tyrosine kinase receptors under 
study and that 9 of them show the ligands PDGFA and/or PDGFB mRNAs, suggests 
the activated state of PDGFRs by means of an autocrine/paracrine loop. SCF mRNA 
was detected in one tumor, but the lack of KIT expression in the same tumor seems 
to exclude the biological role of c-kit activation in this instance. 
The homodimeric or heterodimeric ligands activate different receptor dimers as 
shown in Figure 3. It is therefore theoretically possible that 9 chordomas have an 
activated PDGFRα and/or PDGFRβ.  
In fact, the phosphorylated form of PDGFRβ, has been detected in a sacral 
chordoma by Western Blot analysis, while in the same study the presence of the 
receptor was postulated in five further samples, after the demonstration of PDGFB 
gene expression (6). 
Based on immunohistochemical analysis, we are the first to report the cell-specific 
localization of PDGFRα and PDGFRβ in SBCs. We observed that both tyrosine 
kinases are always expressed in the stromal component of the tumor tissue, while 
the neoplastic cells show a diffuse pattern of expression only in a few tumors. These 
findings suggest that Imatinib mesylate pharmacological activity might be efficiently 
exerted in the stroma. 
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Stromal cells play essential roles in tumor determination: they constitute a solid 
substrate for tumor growth, are involved in tumor neo-angiogenesis and secrete 
growth factors (7). 
The biological contribution of stroma in the behavior of solid tumors and the 
significant stromal component in chordoma pinpoint a putative pharmacological 
action of Imatinib mesylate against chordoma. The reported colliquation of the spinal 
chordoma mass in a single case following the administration of Imatinib is consistent 
with the hypothesis of stromal plot necrosis. Casali and colleagues describe midterm 
signs of a decrease in tumor density on the CT scan and a change in the signal 
intensity on the MRI scan even without a noticeable impact on tumor size, which 
indeed also may increase (6). 
This effect of Imatinib on the tumor mass might be dependent on the amount of the 
stromal component of the tumor and can lead to different consequences according to 
its localization. Tumor swelling in sacral chordomas usually doesn’t lead to any 
serious or life-threatening clinical situations. An increase in tumor volume in clival 
chordomas could lead to the possible onset of new neurological deficits and 
eventually death for breathing failure due to the worsening of a preexisting brainstem 
compression. However further observations on additional tumors are necessary to 
appreciate the effect of the treatment on chordomas. 
Therefore the above considerations would suggest that the Imatinib use might be 
indicated in the treatment of chordomas with specific localizations and carefully 
considered when a preexisting compression of neurological vital structures has been 
assessed; furthermore its efficacy might be reduced in chordomas with a low stromal 
component. The response of the stromal component of chordoma, following the 
administration of Imatinib mesylate, should be delineated in further studies. 
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This work provides new insights on localization of Imatinib targets in chordoma and 
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Figure 1. Expression of c-kit, PDGFRα, PDGFRβ and their ligands SCF, PDGFA and 
PDGFB and in 15 chordoma samples by immunohistochemical analysis. +, positive. 
-, negative. f, focal expression. * data obtained by RT-PCR. 
 
Figure 2. Immunohistochemical analysis showing (A) PDGFRα expression in stromal 
and tumor cells of chordoma sample 12; (B) PDGFRα immunoreactivity limited to the 
stromal component of chordoma sample 49; (C) PDGFRβ expression in stromal and 
tumor cells chordoma sample 20; (D) PDGFRβ is present mainly in the stromal cells 
with a more limited expression in tumor cell chordoma sample 21. In A, C and D, the 
original magnification is 400x, in B 200x. Open arrow indicates the neoplastic cells, 
black arrow indicates stromal cells. 
 
Figure 3. Schematic representation of PDGFRαα PDGFRαβ and PDGFRββ 
activation mechanism upon binding with their ligands PDGFAA, PDGFAB and 
PDGFBB. Black dots indicate the activated status of receptors.  
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